All In Biotech

Drug Trial Radar · NCT07875413

Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy

A Multi-center, Phase 2 Clinical Study of an Autologous Anti-CD19/CD20 Chimeric Antigen Receptor T-Cell Therapy, Prizloncabtagene Autoleucel (Prizlon-cel), for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

55

Planned (sponsor's estimate)

Start

May 2027

Primary completion

Jun 2029

Study completion Dec 2030

Sponsor

Lead sponsor
AbelZeta Inc.Industry
Sponsor type
Industry
First posted
Oct 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 2, multicenter, open-label study will evaluate the safety and efficacy of a single infusion of Prizloncel, an anti-CD19/CD20 chimeric antigen receptor T cells following lymphodepleting chemotherapy in participants with relapsed/refractory (r/r) diffuse large B-cell lymphoma post FDA approved, commercially available CAR T-cell therapy Approximately 50 participants will undergo leukapheresis, lymphodepletion with fludarabine and cyclophosphamide, and infusion of Prizlon-cel. Participants will be followed for 24 months (approximately 2 years) to evaluate efficacy, safety, CAR T-cell persistence, pharmacokinetics/pharmacodynamics, and biomarkers. Long-term safety follow-up for gene therapy-related events will continue for up to 15 years following CAR T-cell infusion.

Conditions

  • Large B Cell Lymphoma
  • LBCL
  • Diffuse Large B Cell Lymphoma (DLBCL)
  • Relapse Diffuse Large B Cell Lymphoma
  • High Grade B Cell Lymphoma
  • FL
  • HGBL
  • Transformed Follicular Lymphoma (TFL)
  • Primary Mediastinal B Cell Lymphoma
  • PMBCL
  • HGBL With MYC and BCL2 and/or BCL6 Rearrangements

Interventions

  • Prizloncabtagene AutoleucelBiological

    An Autologous anti-CD19/CD20 chimeric antigen receptor T-cell therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR)Time frame: Through Month 24
  2. Incidence and severity of adverse events (AEs)Time frame: Through Month 24

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Gilbert, Arizona

  • Research Site

    La Jolla, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.